Altos Labs Stock Price, Valuation & IPO
Private company — Altos Labs is privately held. Its shares are not listed on any public exchange and can only be accessed through private secondary transactions.
Status source: AXEVIL investment team
$19.18 per share (AXEVIL consensus estimate)
Source: AXEVIL consensus of recent secondary transactions · as of 27 October 2026
Last round valuation: $6.3B
Source: C, February 2024, post-money
Total raised: $3B
Data last updated: 27 October 2026
About Altos Labs
Develops partial cellular reprogramming that restores a youthful gene expression pattern to treat age-related diseases. Launched in 2022 with $3 billion in investor commitments, CEO Hal Barron from GSK, approximately 550 employees in the US and UK.
Altos Labs is an American-British biotechnology company, launched in January 2022 in Redwood City with an industry-record $3 billion in investor commitments. It focuses on cellular reprogramming: cell rejuvenation as a way to treat kidney, liver, heart, and lung diseases, which share a common cause — the aging of the cells themselves. The company is led by former GSK head of research Hal Barron and Hans Bishop, who sold Juno to Celgene for $9 billion; it has about 550 employees, and among its directors and advisors are three Nobel laureates: Jennifer Doudna, Frances Arnold, and Shinya Yamanaka. In 2025, Dorian Therapeutics was acquired, and a paper on mesenchymal drift was published in Cell. There are no announced clinical programs yet.
- Sector: Healthcare & Biotech
- Headquarters: Redwood City, California, USA
- Founded: 2021
Key highlights
- Kidney disease as accelerated aging. Kunzhang's group from Altos showed in Nature Aging that diseased kidney cells age epigenetically faster and replicate the path of normal aging. If the disease is indeed accelerated aging, reprogramming can reverse it.
- Weaker drift, patients live longer. The Belmonte Group found mesenchymal drift in dozens of human tissues in Cell. In idiopathic pulmonary fibrosis, survival was shorter the stronger the drift, and the pulse of Yamanaka factors reduced it.
- Donor organs as a shortcut to people. Klausner said in 2024 that old rat kidneys were treated for 45 minutes with a cocktail of factors before transplantation, and after it, the organs worked. The results have not yet been published.
Funding rounds
| Date | Round | Price / share | Post-money valuation |
|---|---|---|---|
| 14 February 2024 | C | $25.02 | $6.3B |
| 25 March 2022 | B | $19.15 | $3.7B |
| 4 September 2021 | A | $8.97 | $1.3B |
Frequently asked questions
How can I buy Altos Labs stock before the IPO?
Not on a public exchange — Altos Labs is privately held. Shares change hands only in private secondary transactions. AXEVIL structures those as dedicated US special purpose vehicles for accredited investors, subject to availability and to the rules of your jurisdiction.
What is the Altos Labs stock price?
A private company has no single official share price. AXEVIL's consensus estimate is $19.18 per share as of 27 October 2026. Its most recent round implied a post-money valuation of $6.3B (February 2024).
What is Altos Labs's valuation (net worth)?
Altos Labs's most recent funding round valued the company at $6.3B post-money (February 2024) — the latest primary-market measure of what the company is worth. Secondary trades can price its shares above or below that round.
When will Altos Labs IPO?
No listing has been announced. AXEVIL does not forecast IPO dates — this page states what has actually been filed or reported, with the date it was last checked.
Is Altos Labs publicly traded?
No. Altos Labs is a private company and its shares are not listed on any public exchange.
Does Altos Labs have a stock symbol?
No. Altos Labs has no ticker symbol because its shares are not listed on any exchange; a symbol is assigned only at an IPO or direct listing.
Similar companies
- Benchling — Healthcare & Biotech
- Neuralink — Healthcare & Biotech
- Chai Discovery — Healthcare & Biotech
- Tenstorrent — Semiconductors
- Impossible Foods — Consumer & Retail
- Automation Anywhere — AI / Enterprise
Risk disclosure
Nothing on this page is an offer to sell or a solicitation to buy any security, and it is not investment advice. Valuations and share prices shown here are AXEVIL estimates built from primary sources — filings, announced rounds and completed secondary transactions — not quoted market prices, and they can be revised. Private-company shares are illiquid, may be impossible to sell, and the entire amount invested can be lost. Availability depends on your jurisdiction and on accredited-investor status.